Lupin has allotted 75,273 equity shares under ESOP on 13 February 2026. In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,40,86,438 consisting of 45,70,43,219 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Net profit of Lupin rose 37.47% to Rs 1175.55 crore in the quarter ended December 2025 as against Rs 855.16 crore during the previous quarter ended December 2024. Sales rose 26.37% to Rs 7100.45 crore in the quarter ended December 2025 as against Rs 5618.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales7100.455618.56 26 OPM %31.8624.13 - PBDT2261.571342.72 68 PBT1948.611071.27 82 NP1175.55855.16 37 Powered by Capital Market - Live News

Lupin announced that the company and its wholly owned subsidiary, Lupin Pharmaceuticals Inc., USA, have entered into a settlement and license agreement with Astellas Pharma Inc., Astellas Ireland Co., and Astellas Pharma Global Development Inc. (collectively Astellas) in respect of a patent infringement dispute related to the company`s product `Mirabegron`. Under the terms of the Agreement, Lupin will pay Astellas (1) USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027. The settlement terms are confidential. Powered by Capital Market - Live News

Lupin announced the launch of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. The product was developed in partnership with Pharmascience Inc. Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80mg, 100 mg, and 140 mg are bioequivalent to Sprycel� Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company, and indicated for the treatment of:- newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase  - adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib  - adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy  - pediatric patients 1 year of age and older with Ph+ CML in chronic phase  - pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapyPowered by Capital Market - Live News

Lupin announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs, and supply chain to ensure global access to Telacebec. Powered by Capital Market - Live News